嗜酸细胞性滤泡性甲状腺癌与经典滤泡性甲状腺癌临床影响的比较
该回顾性研究纳入378例接受甲状腺切除术及初始碘-131治疗的滤泡性甲状腺癌患者(嗜酸细胞性126例,经典滤泡性252例),随访中位6.9年。结果显示嗜酸细胞性患者复发率更高(17% vs 8%),无病生存期更短,但疾病特异性生存和总生存无显著差异。
要点
- 嗜酸细胞性滤泡性甲状腺癌复发率显著高于经典滤泡性癌(17% vs 8%)。
- 嗜酸细胞性患者无病生存期更短,为其唯一独立预后因素。
- 两组疾病特异性生存和总生存无显著差异。
核心结论
- 嗜酸细胞性滤泡性甲状腺癌患者复发更常见,无病生存预后更差,应与经典滤泡性癌分开分类。
- 但初始碘-131治疗后,两组总生存和疾病特异性生存无显著差异。
研究设计与样本
- 回顾性评估378例诊断为嗜酸细胞性滤泡性甲状腺癌(N=126)或经典滤泡性甲状腺癌(N=252)的患者。
- 患者均接受甲状腺切除术和补充碘-131放射性碘治疗,随访中位6.9年(四分位距3.7;11.7年)。
- 采用单因素和多因素分析识别与疾病相关生存和总生存相关的因素。
主要发现
- 随访期间嗜酸细胞性患者复发诊断显著更频繁(17% vs 8%;p值0.037)。
- 嗜酸细胞性患者平均无病生存期缩短为17.9年(95%CI 16.0-19.8),经典滤泡性癌为20.1年(95%CI 19.0-21.1)(p值0.027)。
- 多因素分析显示嗜酸细胞性为无病生存的唯一独立预后因素(HR 0.502;95%CI 0.309-0.816)。
- 嗜酸细胞性患者远处转移的碘亲和性显著更低(p值0.014)。
- 中位随访6.9年(3.7;11.7年)期间,平均疾病特异性生存和总生存无显著差异(p值分别为0.671和0.687)。
临床怎么用
- 对嗜酸细胞性滤泡性甲状腺癌患者应加强随访监测复发。
- 嗜酸细胞性滤泡性甲状腺癌远处转移碘亲和性较低,需考虑其他评估或治疗策略。
局限性
- 为回顾性研究设计。
- 随访时间中位6.9年,可能不足以评估长期生存差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT). METHODS: We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival. RESULTS: Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0-19.8) vs. 20.1 years (95% CI 19.0-21.1) in FTC patients (p value 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309-0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years). CONCLUSIONS: Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT.
引用
- Wenter V, Albert NL, Unterrainer M, et al. Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 32683470. doi:10.1007/s00259-020-04952-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。